Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
about
Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluationThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyPegvisomant in acromegaly: an update.Management of acromegaly in Latin America: expert panel recommendationsA pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans.Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineLong-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDYMedical therapy of acromegalyLong-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant.Pegvisomant in acromegaly: why, when, how.Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.Pharmacotherapy for adults with tumors of the central nervous system.The role of primary pharmacological therapy in acromegaly.Octreotide LAR: safety and tolerability issues.Medical therapy in acromegaly.Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.Investigational therapies for acromegaly.Aggressive tumors and difficult choices in acromegaly.Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status.Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response.Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.Current management practices for acromegaly: an international survey.A case of an acromegalic patient resistant to the recommended maximum GH receptor antagonist dosage.The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.Dose optimization of somatostatin analogues for acromegaly patients.Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.How to improve effectiveness of pegvisomant treatment in acromegalic patients.
P2860
Q21254711-0AE60FEA-FACB-43D2-BA28-434C07D2E448Q26796357-12782FAE-D1E5-42BD-8D6F-C678B353518FQ33725999-6E70F19A-F33D-44D4-979A-869211D0EA5BQ33794388-22DE15BF-ADF8-4120-955C-642F2512FB24Q34032058-DFF8BCC8-DF41-47E5-95E8-EBC74E75F526Q34277844-FA5E969D-C0B0-4FAD-AEB0-7CFA8A7D9364Q34446297-3CABD56B-3076-49F5-88DB-99BE5585E271Q35895856-BEFD775E-6826-4D2D-8E22-DBDCD9893FC7Q36119677-784497DA-270C-4632-B848-C8049306362BQ36834979-212203F7-2B1E-4F36-B08A-FFB8FCBF2E02Q36965612-65D8CEFA-05F1-4F9A-BBFC-8A5BE5B77225Q37321948-01322AA8-5D90-4769-BC73-A749612057FDQ37353276-3EA1342D-EE5F-436A-98A6-692F065E473AQ37531005-359B5C9D-1DFF-4F53-8404-D68CCE1D0C18Q37649647-E7DA71F4-B710-472C-80C3-8E3DBEA50779Q37859250-B6E59BDF-23A2-4E43-9744-0C28D5760D80Q37895525-1981237A-38EA-408B-BD4D-474A6BCB24D8Q38111437-B278A9F6-4097-4459-ABF8-97612B95E31DQ38167711-7438AD25-5C91-4F0E-B070-3340191074FDQ38185334-BAC2355F-B8C3-4B72-A09B-7DBDD880ABCFQ38683309-04A21C95-CD05-4BE2-AFA1-0E1B2DAEB280Q39064562-36D79B6A-AF8E-4A6B-8A5E-23E42CD73C02Q39146196-240B4CA5-1811-49B5-9AFE-E4E67D7023B6Q39294965-89F71D17-5CD6-40A2-8A10-D3B7156A65BEQ39687911-D0DDD122-0805-41EC-84F4-17B8A22618FBQ39818772-1F2E5BAB-BEA1-414F-A3E4-B039809997DFQ42546777-062319BD-BCCB-44A2-95D3-601BCB9E5375Q42993983-794A94FE-74B7-43AB-82CC-840FDCA18DA1Q43116265-44B97203-8396-4790-A264-03CA0E431A3FQ43222345-B7BBA975-1ECD-45E2-AA78-6771E4CA64C3Q44054768-BA2A182C-AA2B-4752-841F-94B64DBFC030Q47130943-91E1365B-F67E-4A23-BFC0-452C701B3B01Q51995940-E6F726E9-194C-4814-BEDF-2D9DFA132D06Q53720920-8F848F63-471A-45BD-968B-FAB887EE45FA
P2860
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Efficacy of 12-month treatment ...... tension and glucose tolerance.
@en
Efficacy of 12-month treatment ...... tension and glucose tolerance.
@nl
type
label
Efficacy of 12-month treatment ...... tension and glucose tolerance.
@en
Efficacy of 12-month treatment ...... tension and glucose tolerance.
@nl
prefLabel
Efficacy of 12-month treatment ...... tension and glucose tolerance.
@en
Efficacy of 12-month treatment ...... tension and glucose tolerance.
@nl
P2093
P50
P356
P1476
Efficacy of 12-month treatment ...... tension and glucose tolerance.
@en
P2093
Christian J Strasburger
Fabio Tortora
Francesco Briganti
Ione A Kourides
Maria Cristina De Martino
Pia Burman
Renata S Auriemma
P304
P356
10.1530/EJE.1.02112
P577
2006-03-01T00:00:00Z